BioPorto Diagnostics

OMX: BIOPOR

DKK570.3m market cap

DKK3.26 last close

BioPorto is a diagnostic company focused on the development and marketing antibodies and other products for research and diagnostics. This includes products marketed for research use and The NGAL Test for the prediction of kidney failure.

Investment summary

In July 2019 BioPorto announced that the FDA had requested additional information for The NGAL Test’s 510(k) application for paediatric acute kidney injury (AKI), although few other details were disclosed. Unfortunately, the existing clinical data set does not include the requested information, so the company will need to withdraw its current application and collect additional samples, which carries additional risk (probability of success lowered to 50% from 60%). The company forecasts that it will be able to refile an application in Q419 if sample collection goes smoothly.

Y/E Dec
Revenue (DKKm)
EBITDA (DKKm)
PBT (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2017A 25.2 (33.1) (34.2) (20.59) N/A N/A
2018A 26.0 (42.1) (42.5) (24.34) N/A N/A
2019E 38.6 (45.9) (45.9) (23.70) N/A N/A
2020E 53.7 (48.3) (48.3) (23.74) N/A N/A
Last updated on 25/07/2019
Industry outlook

The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.

Last updated on 25/07/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (DKKm) 43
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (17.2) (18.5) (6.9)
Relative* (17.3) (18.9) (5.1)
52-week high/low DKK6.2/DKK3.2
*% relative to local index
Key management
Thomas Magnussen Chairman
Peter Mørch Eriksen CEO
Ole Larsen CFO
Jan Kuhlmann Andersen COO